Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sven Stodtmann"'
Autor:
Diego Valderrama, Ana Victoria Ponce‐Bobadilla, Sven Mensing, Holger Fröhlich, Sven Stodtmann
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 1, Pp 41-53 (2024)
Abstract Recently, the use of machine‐learning (ML) models for pharmacokinetic (PK) modeling has grown significantly. Although most of the current approaches use ML techniques as black boxes, there are only a few that have proposed interpretable ar
Externí odkaz:
https://doaj.org/article/b01c91b33a9843feb724d969b1c2d471
Autor:
Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In‐Ho Song, Peter Wung, Wei Liu, Mohamed‐Eslam F. Mohamed
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 2, Pp n/a-n/a (2024)
Abstract Upadacitinib is an orally administered, selective, Janus kinase inhibitor that is approved for several auto‐immune conditions, such as axial spondyloarthritis, an inflammatory rheumatic disease that includes ankylosing spondylitis (AS) and
Externí odkaz:
https://doaj.org/article/0555cf245c5a4ec08279231b06dd5a7d
Autor:
Sven Stodtmann, Ahmed Nader, Akshanth R. Polepally, Ahmed A. Suleiman, Insa Winzenborg, Peter Noertersheuser, Juki Ng, Nael M. Mostafa, Mohamad Shebley
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1611-1619 (2021)
Abstract Elagolix is a novel, oral gonadotropin‐releasing hormone receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. Consistent wi
Externí odkaz:
https://doaj.org/article/bdc368c4a22d4730855a7980b67fdb9e
Autor:
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Mong-Jen Chen, Insa Winzenborg, Sven Mensing, Jonas Blaes, Tobias Haslberger, Loic Laplanche, Ingeborg Dreher, Nael M. Mostafa
Publikováno v:
Clinical Pharmacokinetics. 62:623-634
Autor:
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, Wen Zhou, Wei Liu, Mohamed-Eslam F. Mohamed
Publikováno v:
Clinical Pharmacokinetics. 62:101-112
Upadacitinib, an oral selective and reversible Janus kinase (JAK) inhibitor, showed favorable efficacy and safety in patients with moderate-to-severe ulcerative colitis (UC). The objective was to characterize upadacitinib pharmacokinetics in UC patie
Autor:
Sven Stodtmann, Doerthe Eckert, Rujuta Joshi, Silpa Nuthalapati, Christine K. Ratajczak, Rajeev Menon, Sven Mensing, Hao Xiong
Publikováno v:
The Journal of Clinical Pharmacology. 62:1236-1246
Autor:
Rajeev M. Menon, Sreeneeranj Kasichayanula, Rujuta Joshi, Sven Mensing, Hao Xiong, Bruce A. Bach, Doerthe Eckert, Sven Stodtmann, Silpa Nuthalapati
Publikováno v:
Journal of Clinical Pharmacology
Veliparib (ABT‐888) is a poly(ADP‐ribose) polymerase inhibitor in development for the treatment of high‐grade ovarian cancer or BRCA‐mutated breast cancer in combination with carboplatin and paclitaxel. The population pharmacokinetics of veli
Autor:
Juki Ng, Akshanth R. Polepally, Sven Stodtmann, Nael M. Mostafa, Peter Noertersheuser, Mohamad Shebley, Ahmed Nader, Insa Winzenborg, Ahmed Abbas Suleiman
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 4, Pp 1611-1619 (2021)
Clinical and Translational Science, Vol 14, Iss 4, Pp 1611-1619 (2021)
Elagolix is a novel, oral gonadotropin‐releasing hormone receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. Consistent with its me
Autor:
Sven Stodtmann, Mong-Jen Chen, Lucia Siovitz, Mareike Bereswill, Andreas Lazar, Nicholas Croft, Jaroslaw Kierkus, William A Faubion, Nael M Mostafa
Publikováno v:
Journal of Crohn'scolitis. 16(10)
Background and Aims The Phase 3 study ENVISION I demonstrated efficacy and safety of adalimumab in paediatric patients with moderate to severe ulcerative colitis. The protocol-specified high-dose adalimumab regimen was numerically more efficacious th
Publikováno v:
The Journal of Clinical Pharmacology. 60:528-539
Upadacitinib (ABT-494) is a selective Janus kinase (JAK)1 inhibitor being developed for treatment of several inflammatory disorders. A population pharmacokinetic model was developed for upadacitinib using 11,658 plasma concentrations from 1145 subjec